ReviewNature reviews. Neurology2024
Parkinson disease psychosis: from phenomenology to neurobiological mechanisms.
Review in Nature reviews. Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward.NeuroSci · 2026Review
- Symptom prevalence and pharmacological management of late-stage Parkinson's disease (LSPD): a cross-sectional, multinational survey.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Parkinson's disease-associated psychosis in a Brazilian sample: prevalence and clinical profile.Arquivos de neuro-psiquiatria · 2026Article
- How to advance the pharmacological management of cognitive impairment in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Imposter in the brain: aetiological, clinical and neuroimaging characteristics of Capgras syndrome.Brain : a journal of neurology · 2026Article
- Management of Parkinson's disease psychosis-a European perspective.The Lancet regional health. Europe · 2026Review
- New-Onset Psychosis in a Person with Parkinson's Disease after "Horny Goat Weed" Use.Movement disorders clinical practice · 2026Article
- Patient and Physician Perspectives on Pharmacotherapy in Parkinson's Disease Psychosis: A Mixed-Methods Exploratory Study.Pharmacy (Basel, Switzerland) · 2026Article
- Parkinson's disease beyond motor symptoms: a review of the validity and limitations of current classification of non-motor symptoms.Frontiers in psychiatry · 2026Review
- Treatment of Parkinson's Disease-Related Psychosis.Clinical pharmacology : advances and applications · 2026Review
- Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis.Nature. Mental health · 2026Article
- Disrupted visual-to-semantic dynamics promote visual hallucinations in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Review
- Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.Schizophrenia bulletin · 2025Review
- Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa.Neurology. Clinical practice · 2025Article
- Long-Term Outcomes in a Parkinson's Disease Minor Phenomena Cohort.Movement disorders clinical practice · 2025Observational
- Protective Effects of Genetic Proxies of Cognitive Reserve in Parkinson's Disease: A Longitudinal Multi-Cohort Study.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Understanding Tau pathology: Insights from animal models.Zoological research · 2025Review
- Neuropsychiatric symptom subtypes and dementia-associated neuropathologic change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson's disease.NPJ Parkinson's disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson disease (PD) psychosis (PDP) is a spectrum of illusions, hallucinations and delusions that are associated with PD throughout its disease course. Psychotic phenomena can manifest from the earliest stages of PD and might follow a continuum from minor hallucinations to structured hallucinations and delusions. Initially, PDP was considered to be a complication associated with dopaminergic drug use. However, subsequent research has provided evidence that PDP arises from the progression of brain alterations caused by PD itself, coupled with the use of dopaminergic drugs. The combined dysfunction of attentional control systems, sensory processing, limbic structures, the default mode network and thalamocortical connections provides a conceptual framework to explain how new incoming stimuli are incorrectly categorized, and how aberrant hierarchical predictive processing can produce false percepts that intrude into the stream of consciousness. The past decade has seen the publication of new data on the phenomenology and neurobiological basis of PDP from the initial stages of the disease, as well as the neurotransmitter systems involved in PDP initiation and progression. In this Review, we discuss the latest clinical, neuroimaging and neurochemical evidence that could aid early identification of psychotic phenomena in PD and inform the discovery of new therapeutic targets and strategies.
Indexed as
Identifiers
38225264What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.